.jpg)
The IPO consisted of a total offering of 2,933,334 new shares, raising a total of EUR 25 million, overallotment included.
At the end of the first trading day, the share price closed at EUR 7.54 in Amsterdam and at EUR 7.6 in Brussels bringing the market capitalisation of OMS at around EUR 75.5 million.
On the electronic orderbook, a total of 123,057 shares were traded in Brussels and Amsterdam, together amounting to a turnover of EUR 934 thousand.
OncoMethylome is a molecular diagnostics company developing gene methylation tests for early cancer detection and personalised treatment decisions. Specifically, OncoMethylome Sciences solutions are designed to assist physicians (i) in detecting cancer at an early stage with a high level of accuracy and (ii) in predicting a patient’s response to cancer therapy or likelihood of cancer recurrence.
The company was founded in 2003. Its offices and laboratories are located in Belgium, the Netherlands and Durham, NC, USA. The company is headquarted in Liège (Belgium).
ICB classification of OncoMethylome: Industry 4000 (Health Care) - Supersector 4500 (Health care) - Sector 4570 (Pharmaceuticals & Biotechnology) – Subsector 4573 Biotechnology.
OncoMethylome is traded on the NSC platform under the following codes:
| Euronext Brussels: | Stock Code: ONCOB |
| ISIN Code: BE0003844611 | |
| SVM Code: 3844.61 | |
| Euronext Amsterdam: | Stock Code: ONCOA |
| ISIN Code: BE0003844611 | |
| Fonds Code: 29065 |
